241 related articles for article (PubMed ID: 14738154)
1. Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways.
Sawafuji K; Miyakawa Y; Weisberg E; Griffin JD; Ikeda Y; Kizaki M
Leuk Lymphoma; 2003 Nov; 44(11):1987-96. PubMed ID: 14738154
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
3. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
[TBL] [Abstract][Full Text] [Related]
4. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells.
Kawauchi K; Ogasawara T; Yasuyama M; Ohkawa Si
Blood Cells Mol Dis; 2003; 31(1):11-7. PubMed ID: 12850478
[TBL] [Abstract][Full Text] [Related]
5. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
Mow BM; Chandra J; Svingen PA; Hallgren CG; Weisberg E; Kottke TJ; Narayanan VL; Litzow MR; Griffin JD; Sausville EA; Tefferi A; Kaufmann SH
Blood; 2002 Jan; 99(2):664-71. PubMed ID: 11781252
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
Donato NJ; Wu JY; Stapley J; Gallick G; Lin H; Arlinghaus R; Talpaz M
Blood; 2003 Jan; 101(2):690-8. PubMed ID: 12509383
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
Yu C; Rahmani M; Almenara J; Subler M; Krystal G; Conrad D; Varticovski L; Dent P; Grant S
Cancer Res; 2003 May; 63(9):2118-26. PubMed ID: 12727828
[TBL] [Abstract][Full Text] [Related]
8. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
[TBL] [Abstract][Full Text] [Related]
9. A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia.
Xia DY; Liu L; Hao MW; Liu Q; Chen RA; Liang YM
Braz J Med Biol Res; 2014 Dec; 47(12):1096-101. PubMed ID: 25387678
[TBL] [Abstract][Full Text] [Related]
10. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
12. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.
Mukai M; Che XF; Furukawa T; Sumizawa T; Aoki S; Ren XQ; Haraguchi M; Sugimoto Y; Kobayashi M; Takamatsu H; Akiyama S
Cancer Sci; 2003 Jun; 94(6):557-63. PubMed ID: 12824882
[TBL] [Abstract][Full Text] [Related]
13. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
Yu C; Krystal G; Dent P; Grant S
Clin Cancer Res; 2002 Sep; 8(9):2976-84. PubMed ID: 12231544
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
Klejman A; Rushen L; Morrione A; Slupianek A; Skorski T
Oncogene; 2002 Aug; 21(38):5868-76. PubMed ID: 12185586
[TBL] [Abstract][Full Text] [Related]
15. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
[TBL] [Abstract][Full Text] [Related]
16. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
Sun X; Layton JE; Elefanty A; Lieschke GJ
Blood; 2001 Apr; 97(7):2008-15. PubMed ID: 11264165
[TBL] [Abstract][Full Text] [Related]
17. Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571.
Yu C; Dai Y; Dent P; Grant S
Cancer Biol Ther; 2002; 1(6):674-82. PubMed ID: 12642693
[TBL] [Abstract][Full Text] [Related]
18. Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.
Lee YL; Chen CW; Liu FH; Huang YW; Huang HM
PLoS One; 2013; 8(4):e61939. PubMed ID: 23613979
[TBL] [Abstract][Full Text] [Related]
19. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.
Kindler T; Breitenbuecher F; Kasper S; Stevens T; Carius B; Gschaidmeier H; Huber C; Fischer T
Leukemia; 2003 Jun; 17(6):999-1009. PubMed ID: 12764361
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells.
Kirschner KM; Baltensperger K
Mol Cancer Res; 2003 Nov; 1(13):970-80. PubMed ID: 14638869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
